Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

United Therapeutics Corporation develops pharmaceuticals to treat vascular diseases such as pulmonary hypertension and peripheral vascular disease. The Company"s lead products are stable synthetic forms of prostacyclin and are delivered orally or subcutaneously.
Website: unither.com



Growth: Pretty weak revenue growth rate 6.8%, there is slowdown compared to average historical growth rates 19.2%. The revenue growth dynamics is moderately stable

Profitability: LTM EBITDA margin is positive, +50.1%. On average the margin is improving unsteadily. Gross margin is high, +87.4%. In the last quarter the company beat the estimated EPS, +7.5%. The company was ahead of estimated EPS in 60% of quarters (showing a gain of -$0.1 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 0.9% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 130.7% higher than minimum and 8.5% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 4.7x by EV / Sales multiple , the company can be 26.6% overvalued

Insiders: For the last 3 months insiders sold company shares on $285.8 mln (-1.306% of cap.)

Key Financials (Download financials)

Ticker: UTHR
Share price, USD:  (0.0%)473.36
year average price 373.20  


year start price 347.71 2025-02-08

min close price 274.70 2025-07-31

max close price 517.13 2025-12-19

current price 473.36 2026-02-07
Common stocks: 45 500 000

Dividend Yield:  0.0%
FCF Yield LTM: 0.9%
EV / LTM EBITDA: 12.9x
EV / EBITDA annualized: 12.3x
Last revenue growth (y/y):  +6.8%
Last growth of EBITDA (y/y):  +13.3%
Historical revenue growth:  +19.2%
Historical growth of EBITDA:  +16.8%
EV / Sales: 6.5x
Margin (EBITDA LTM / Revenue): 50.1%
Fundamental value created in LTM:
Market Cap ($m): 21 538
Net Debt ($m): -1 340
EV (Enterprise Value): 20 198
Price to Book: 3.3x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2026-01-22businesswire.com

United Therapeutics Corporation Announces Appointment of Kevin J. Tracey to its Board of Directors

2026-01-13seekingalpha.com

United Therapeutics Corporation (UTHR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

2025-12-11zacks.com

Here's Why United Therapeutics (UTHR) is a Strong Momentum Stock

2025-11-04zacks.com

Why United Therapeutics (UTHR) is a Top Growth Stock for the Long-Term

2025-10-29zacks.com

United Therapeutics (UTHR) Beats Q3 Earnings Estimates

2025-10-01zacks.com

Is IPF the Next Big Market Opportunity for United Therapeutics?

2025-09-28seekingalpha.com

United Therapeutics Corporation - Special Call

2025-09-03forbes.com

United Therapeutics: Is UTHR Stock Still A Buy At $400?

2025-09-02proactiveinvestors.com

United Therapeutics shares jump on positive lung disease study results

2025-08-27seekingalpha.com

United Therapeutics: Critical September IPF Data Catalyst Sets Up Momentous Year
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-05-01 2023-11-01 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-10-29 06:32:18 2025-07-30 06:34:20 2025-02-26 06:33:08 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26 2022-02-24 06:05:01 2021-02-24 06:07:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 800M 799M 2 877M 749M 715M 678M 2 328M 609M 597M 507M 1 936M 516M 1 686M 1 483M
costOfRevenue 101M 88M 310M 83M 78M 73M 258M 70M 64M 52M 147M 37M 123M 108M
grossProfit 699M 711M 2 568M 666M 637M 605M 2 070M 539M 532M 455M 1 790M 479M 1 563M 1 375M
grossProfitRatio 0.874 0.89 0.889 0.891 0.892 0.885 0.893 0.897 0.928
researchAndDevelopmentExpenses 128M 134M 481M 104M 140M 104M 408M 85M 89M 83M 323M 66M 540M 358M
generalAndAdministrativeExpenses 0 160M 542M 199M 152M 121M 395M 107M 110M 70M 416M 81M 403M 369M
sellingAndMarketingExpenses 0 31M 96M 21M 25M 23M 82M 21M 20M 17M 71M 17M 64M 55M
sellingGeneralAndAdministrativeExpenses 183M 191M 639M 219M 178M 144M 477M 128M 130M 87M 487M 98M 467M 424M
otherExpenses 0 22M 71M 0 800 000 2M 0 -5M -600 000 -8M 0 0 0 0
operatingExpenses 310M 347M 1 191M 323M 317M 249M 885M 212M 219M 170M 810M 165M 1 007M 782M
costAndExpenses 411M 434M 1 500M 406M 395M 321M 1 143M 282M 283M 223M 957M 202M 1 130M 890M
interestIncome 46M 51M 199M 50M 46M 54M 163M 45M 37M 29M 45M 13M 17M 29M
interestExpense 3M 7M 43M 10M 12M 13M 59M 16M 15M 14M 32M 9M 19M 24M
depreciationAndAmortization 22M 21M 73M 19M 19M 15M 53M 40M 37M 35M 51M 20M 50M 50M
ebitda 463M 437M 1 654M 418M 339M 427M 1 387M 367M 350M 319M 1 040M 335M 737M 646M
ebitdaratio 0.579 0.547 0.558 0.474 0.63 0.603 0.587 0.629 0.648
operatingIncome 389M 365M 1 377M 343M 320M 356M 1 185M 327M 313M 284M 980M 314M 556M 594M
operatingIncomeRatio 0.486 0.456 0.458 0.447 0.526 0.537 0.525 0.561 0.609
totalOtherIncomeExpensesNet 50M 44M 162M 46M 35M 2M 89M -5M -600 000 8M -29M -2M 38M 45M
incomeBeforeTax 438M 408M 1 539M 389M 355M 399M 1 274M 352M 335M 292M 951M 313M 594M 639M
incomeBeforeTaxRatio 0.548 0.511 0.519 0.497 0.588 0.577 0.562 0.576 0.606
incomeTaxExpense 99M 99M 344M 80M 77M 92M 290M 84M 76M 51M 223M 73M 118M 124M
netIncome 339M 310M 1 195M 309M 278M 307M 985M 268M 259M 241M 727M 239M 476M 515M
netIncomeRatio 0.424 0.388 0.413 0.389 0.452 0.439 0.435 0.475 0.464
eps 7.73 6.86 26.44 6.93 6.26 6.52 21.04 5.71 5.53 5.2 15.98 5.26 10.6 11.65
epsdiluted 7.16 6.41 6.39 5.85 6.17 5.38 5.24 4.86 4.91
weightedAverageShsOut 44M 45M 45M 45M 44M 47M 47M 47M 47M 46M 46M 46M 45M 44M
weightedAverageShsOutDil 47M 48M 49M 48M 48M 50M 50M 50M 50M 50M 49M 49M 47M 45M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-21 2023-02-22 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 156M 103M 13M -2M 5M
ebit 1 582M 1 334M 989M 687M 596M
nonOperatingIncomeExcludingInterest -205M -149M -9M -131M -3M
netIncomeFromContinuingOperations 1 195M 985M 727M 476M 515M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome 1 195M 985M 727M 476M 515M
epsDiluted 24.64 19.81 15 10.06 11.54

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-05-01 2023-11-01 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-10-29 06:32:18 2025-07-30 06:34:20 2025-02-26 06:33:08 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26 2022-02-24 06:05:01 2021-02-24 06:07:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 1 137M 1 593M 1 697M 1 554M 1 356M 1 252M 1 208M 1 108M 1 067M 1 164M 961M 967M 895M 739M
shortTermInvestments 1 631M 1 456M 1 570M 1 773M 1 616M 1 456M 1 786M 3 829M 3 635M 1 700M 1 878M 1 649M 1 036M 1 096M
cashAndShortTermInvestments 2 768M 3 049M 3 267M 3 327M 2 972M 2 708M 2 994M 4 936M 4 703M 2 863M 2 839M 2 616M 1 931M 1 835M
netReceivables 298M 379M 279M 342M 291M 307M 279M 259M 273M 135M 220M 232M 199M 157M
inventory 177M 169M 158M 147M 137M 120M 112M 104M 103M 103M 102M 91M 94M 87M
otherCurrentAssets 252M 230M 170M 185M 221M 113M 166M 1 988M 1 770M 93M 219M 118M 100M 88M
totalCurrentAssets 3 494M 3 827M 3 874M 4 000M 3 620M 3 249M 3 551M 3 459M 3 213M 3 193M 3 380M 3 056M 2 324M 2 167M
propertyPlantEquipmentNet 1 556M 1 362M 1 222M 1 157M 1 095M 1 074M 1 045M 992M 939M 897M 862M 841M 781M 732M
goodwill 0 0 32M 0 0 0 34M 0 0 0 28M 28M 28M 28M
intangibleAssets 117M 112M 80M 112M 115M 115M 81M 44M 0 0 17M 17M 17M 130M
goodwillAndIntangibleAssets 117M 112M 112M 112M 115M 115M 114M 44M 45M 45M 45M 45M 45M 158M
longTermInvestments 1 656M 1 918M 1 475M 1 279M 1 359M 1 492M 1 910M 2 061M 2 024M 1 766M 1 316M 1 444M 1 650M 1 150M
taxAssets 355M 456M 458M 391M 396M 396M 395M 326M 326M 322M 328M 281M 262M 239M
otherNonCurrentAssets 174M 233M 222M 184M 139M 169M 152M 142M 135M 125M 114M 115M 108M 170M
totalNonCurrentAssets 3 857M 4 081M 3 490M 3 123M 3 104M 3 247M 3 616M 3 565M 3 468M 3 153M 2 664M 2 725M 2 846M 2 448M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 7 351M 7 908M 7 364M 7 123M 6 723M 6 495M 7 167M 7 024M 6 681M 6 346M 6 045M 5 782M 5 169M 4 615M
accountPayables 468M 432M 6M 364M 325M 305M 6M 333M 0 0 4M 0 4M 4M
shortTermDebt 0 0 300M 400M 400M 400M 400M 300M 0 0 0 0 0 0
taxPayables 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 -305M 0 -333M 0 0 0 0 0 0
otherCurrentLiabilities 78M 95M 432M 110M 107M 461M 41M 444M 370M 325M 13M 316M 248M 20M
totalCurrentLiabilities 546M 527M 738M 873M 832M 861M 804M 744M 370M 325M 343M 316M 305M 323M
longTermDebt 0 0 0 0 100M 200M 300M 500M 800M 800M 800M 800M 800M 800M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 215M 207M 182M 149M 94M 97M 78M 67M 100M 98M 105M 904M 105M 97M
totalNonCurrentLiabilities 215M 207M 182M 149M 194M 297M 378M 567M 900M 898M 905M 904M 905M 897M
otherLiabilities 0 0 0 0 0 0 0 0 0 0 0 0 0 0
capitalLeaseObligations 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilities 761M 734M 920M 1 022M 1 026M 1 157M 1 182M 1 312M 1 270M 1 223M 1 248M 1 219M 1 210M 1 220M
preferredStock 0 0 0 0 0 0 0 0 0 0 0 0 0 0
commonStock 800 000 800 000 800 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000 700 000
retainedEarnings 8 193M 7 854M 7 222M 6 921M 6 612M 6 334M 6 027M 5 810M 5 542M 5 283M 5 042M 4 910M 4 315M 3 839M
accumulatedOtherComprehensiveIncomeLoss 100 000 0 -3M 7M -15M -16M -13M -44M -51M -39M -56M -84M -23M -14M
othertotalStockholdersEquity -1 603M -681M -828M -900M -981M -55M -82M -122M -265M
totalStockholdersEquity 6 590M 7 174M 6 444M 6 101M 5 697M 5 338M 5 985M 5 712M 5 411M 5 123M 4 797M 4 562M 3 959M 3 395M
totalEquity 6 590M 7 174M 6 444M 6 101M 5 697M 5 338M 5 985M 5 712M 5 411M 5 123M 4 797M 4 562M 3 959M 3 395M
totalLiabilitiesAndStockholdersEquity 7 351M 7 908M 7 123M 6 723M 6 495M 7 024M 6 681M 6 346M 5 782M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 7 351M 7 908M 7 364M 7 123M 6 723M 6 495M 7 167M 7 024M 6 681M 6 346M 6 045M 5 782M 5 169M 4 615M
totalInvestments 3 287M 3 373M 3 045M 3 052M 2 975M 1 492M 3 696M 2 061M 2 024M 1 766M 3 194M 3 093M 2 686M 2 246M
totalDebt 0 0 300M 400M 500M 600M 700M 500M 800M 800M 800M 800M 800M 800M
netDebt -1 137M -1 593M -1 397M -1 154M -856M -652M -508M -608M -267M -364M -161M -167M -95M 61M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-21 2023-02-22 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 279M 279M 220M 199M 157M
otherReceivables 0 0 0 0 0
prepaids 0 0 0 0 0
totalPayables 6M 6M 4M 4M 4M
otherPayables 0 0 0 0 0
accruedExpenses 0 358M 326M 54M 299M
capitalLeaseObligationsCurrent 0 0 0 0 0
capitalLeaseObligationsNonCurrent 0 0 0 0 0
treasuryStock -3 475M -2 579M -2 579M -2 579M -2 579M
additionalPaidInCapital 2 699M 2 549M 2 388M 2 245M 2 149M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR UTHR
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M 1M
fillingDate 2025-10-29 2025-07-30 2024-10-30 2024-07-31 2024-05-01 2023-11-01 2023-08-02 2023-05-03 2022-11-02
acceptedDate 2025-10-29 06:32:18 2025-07-30 06:34:20 2025-02-26 06:33:08 2024-10-30 06:32:28 2024-07-31 06:31:21 2024-05-01 06:32:23 2024-02-21 06:03:30 2023-11-01 06:03:05 2023-08-02 06:02:57 2023-05-03 06:04:18 2023-02-22 06:03:42 2022-11-02 06:03:26 2022-02-24 06:05:01 2021-02-24 06:07:56
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome 339M 310M 1 195M 309M 278M 307M 985M 268M 259M 241M 727M 239M 476M 515M
depreciationAndAmortization 22M 21M 73M 19M 19M 15M 53M 13M 13M 13M 51M 13M 50M 50M
deferredIncomeTax 0 0 0 0 -4M 0 0 -3M -3M 0 0 0 0 0
stockBasedCompensation 39M 38M 144M 42M 50M 26M 39M 21M 14M -12M 107M -2M 139M 164M
changeInWorkingCapital 163M -203M -60M 13M -109M 40M -98M 11M -139M 127M -141M -7M -174M 63M
accountsReceivables 82M -57M -400 000 -51M 17M -28M -59M 14M -138M 86M -22M -58M -41M -6M
inventory -18M -7M -47M -11M -15M -9M -14M -3M -1 000 000 -3M -13M -600 000 -8M 10M
accountsPayables 31M 0 0 33M 26M 2M 0 4M 78M 3M 0 0 0 0
otherWorkingCapital 67M -138M -13M 42M -136M 76M -26M -4M -78M 41M -106M 52M -125M 59M
otherNonCashItems -100 000 26M -24M -6M 54M -11M -1M 36M -37M 6M 58M 16M 108M -36M
netCashProvidedByOperatingActivities 562M 192M 1 327M 377M 232M 377M 978M 346M 106M 375M 803M 259M 598M 756M
investmentsInPropertyPlantAndEquipment -211M -62M -247M -77M -45M -38M -230M -66M -45M -41M -139M -69M -121M -59M
acquisitionsNet 0 0 -31M 0 0 0 -89M 237M 179M 0 -2M 0 0 0
purchasesOfInvestments -416M -1 807M -1 646M -408M -231M -529M -2 514M -645M -672M -890M -1 709M -270M -1 895M -2 309M
salesMaturitiesOfInvestments 183M 1 570M 2 369M 387M 197M 1 307M 2 137M 408M 493M 710M 1 034M 246M 1 529M 1 627M
otherInvestingActivites 585M -600 000 -18M -400 000 -4M -248M -183M 0 -2M
netCashUsedForInvestingActivites 141M -300M -115M -80M 735M -313M -227M -221M -94M
debtRepayment 0 -212M -100M -100M -100M 0 0 0 0
commonStockIssued 45M 18M 0 0 4M 8M 0 61M 0
commonStockRepurchased -1 000M 0 -1 012M -400 000 -12M -1 000M -14M -200 000 0 -14M -11M -300 000 -11M -4M
dividendsPaid 0 0 0 0 0 0 0 0 0
otherFinancingActivites -500 000 -5M 36M 64M -14M -200 000 25M 700 000 7M
netCashUsedProvidedByFinancingActivities -956M -199M -64M -48M -1 068M 8M 25M 49M 7M
effectOfForexChangesOnCash 0 0 0 0 0 0 0 0 107M 0 0 0 0 0
netChangeInCash -253M -307M 490M 198M 104M 44M 247M 40M -96M 202M 66M 172M 156M 300 000
cashAtEndOfPeriod 1 340M 1 593M 1 697M 1 554M 1 356M 1 252M 1 208M 1 108M 1 067M 1 164M 961M 967M 895M 739M
cashAtBeginningOfPeriod 1 593M 1 900M 1 208M 1 356M 1 252M 1 208M 961M 1 067M 1 164M 961M 895M 795M 739M 738M
operatingCashFlow 562M 192M 1 327M 377M 232M 377M 978M 346M 106M 375M 803M 259M 598M 756M
capitalExpenditure -211M -62M -247M -77M -45M -38M -230M -66M -45M -41M -139M -69M -121M -59M
freeCashFlow 352M 130M 1 081M 301M 187M 338M 748M 281M 62M 334M 664M 190M 477M 696M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-26 2024-02-21 2023-02-22 2022-02-24 2021-02-24
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities -29M -23M 4M 0 2M
netCashProvidedByInvestingActivities 417M -720M -812M -487M -739M
netDebtIssuance -400M -100M 0 0 -50M
longTermNetDebtIssuance 0 -100M 0 0 -50M
shortTermNetDebtIssuance -400M 0 0 0 0
netStockIssuance -1 012M -14M -11M -11M -4M
netCommonStockIssuance -1 012M -14M -11M -11M -4M
commonStockIssuance 0 0 0 0 0
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 157M 102M 87M 56M 37M
netCashProvidedByFinancingActivities -1 255M -12M 75M 45M -17M
incomeTaxesPaid 401M 333M 276M 153M 93M
interestPaid 40M 56M 29M 16M 21M

Earning call transcript

2025 q3
2025-10-29 ET (fiscal 2025 q3)
2025 q2
2025-07-30 ET (fiscal 2025 q2)
2025 q1
2025-04-30 ET (fiscal 2025 q1)
2024 q4
2025-02-26 ET (fiscal 2024 q4)
2024 q3
2024-10-30 ET (fiscal 2024 q3)
2024 q2
2024-07-31 ET (fiscal 2024 q2)
2024 q1
2024-05-01 ET (fiscal 2024 q1)
2023 q4
2024-02-21 ET (fiscal 2023 q4)
2023 q3
2023-11-01 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-03 ET (fiscal 2023 q1)
2022 q4
2023-02-22 ET (fiscal 2022 q4)
2022 q3
2022-11-02 ET (fiscal 2022 q3)
2022 q2
2022-08-03 ET (fiscal 2022 q2)
2022 q1
2022-05-04 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-10-29 10:34 ET
United Therapeutics published news for 2025 q3
SEC form 8
2025-10-29 10:34 ET
United Therapeutics published news for 2025 q3
SEC form 10
2025-10-29 10:32 ET
United Therapeutics reported for 2025 q3
SEC form 8
2025-07-30 10:36 ET
United Therapeutics published news for 2025 q2
SEC form 8
2025-07-30 10:36 ET
United Therapeutics published news for 2025 q2
SEC form 10
2025-07-30 10:34 ET
United Therapeutics reported for 2025 q2
SEC form 10
2025-04-30 00:00 ET
United Therapeutics reported for 2025 q1
SEC form 8
2025-04-30 00:00 ET
United Therapeutics published news for 2025 q1
SEC form 8
2025-04-30 00:00 ET
United Therapeutics published news for 2025 q1
SEC form 10
2025-02-26 00:00 ET
United Therapeutics reported for 2024 q4
SEC form 8
2025-02-26 00:00 ET
United Therapeutics published news for 2024 q4
SEC form 8
2025-02-26 00:00 ET
United Therapeutics reported for 2024 q4
SEC form 8
2024-10-30 06:34 ET
United Therapeutics published news for 2024 q3
SEC form 8
2024-10-30 06:34 ET
United Therapeutics published news for 2024 q3
SEC form 10
2024-10-30 06:32 ET
United Therapeutics reported for 2024 q3
SEC form 10
2024-10-30 00:00 ET
United Therapeutics published news for 2024 q3
SEC form 8
2024-07-31 06:33 ET
United Therapeutics published news for 2024 q2
SEC form 8
2024-07-31 06:33 ET
United Therapeutics published news for 2024 q2
SEC form 10
2024-07-31 06:31 ET
United Therapeutics reported for 2024 q2
SEC form 10
2024-07-31 00:00 ET
United Therapeutics published news for 2024 q2
SEC form 8
2024-05-01 06:34 ET
United Therapeutics published news for 2024 q1
SEC form 8
2024-05-01 06:34 ET
United Therapeutics published news for 2024 q1
SEC form 10
2024-05-01 06:32 ET
United Therapeutics reported for 2024 q1
SEC form 10
2024-05-01 00:00 ET
United Therapeutics published news for 2024 q1
SEC form 8
2024-02-21 06:05 ET
United Therapeutics published news for 2023 q4
SEC form 8
2024-02-21 06:05 ET
United Therapeutics reported for 2023 q4
SEC form 8
2024-02-21 06:05 ET
United Therapeutics published news for 2023 q4
SEC form 10
2024-02-21 06:03 ET
United Therapeutics reported for 2023 q4
SEC form 10
2024-02-21 00:00 ET
United Therapeutics published news for 2023 q4
SEC form 8
2023-11-01 06:05 ET
United Therapeutics published news for 2023 q3
SEC form 10
2023-11-01 06:03 ET
United Therapeutics reported for 2023 q3
SEC form 10
2023-11-01 00:00 ET
United Therapeutics published news for 2023 q3
SEC form 6
2023-08-02 06:05 ET
United Therapeutics published news for 2023 q2
SEC form 10
2023-08-02 06:02 ET
United Therapeutics reported for 2023 q2
SEC form 10
2023-08-02 00:00 ET
United Therapeutics published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-07-24 16:30 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-07-14 16:31 ET
United Therapeutics published news for 2023 q2
SEC form 6
2023-06-28 06:47 ET
United Therapeutics published news for 2023 q1
SEC form 10
2023-05-03 00:00 ET
United Therapeutics published news for 2023 q1
SEC form 8
2023-05-03 00:00 ET
United Therapeutics published news for 2023 q1
SEC form 6
2023-03-31 16:30 ET
United Therapeutics published news for 2022 q4
SEC form 6
2023-02-22 06:06 ET
United Therapeutics published news for 2022 q4
SEC form 10
2023-02-22 06:03 ET
United Therapeutics reported for 2022 q4
SEC form 10
2023-02-22 00:00 ET
United Therapeutics reported for 2022 q4
SEC form 8
2023-02-22 00:00 ET
United Therapeutics reported for 2022 q4
SEC form 6
2023-01-09 06:03 ET
United Therapeutics published news for 2022 q4
SEC form 6
2022-11-02 06:05 ET
United Therapeutics published news for 2022 q3
SEC form 10
2022-11-02 06:03 ET
United Therapeutics reported for 2022 q3
SEC form 10
2022-11-02 00:00 ET
United Therapeutics reported for 2022 q3
SEC form 8
2022-11-02 00:00 ET
United Therapeutics reported for 2022 q3
SEC form 6
2022-10-11 07:15 ET
United Therapeutics published news for 2022 q3
SEC form 6
2022-09-20 06:00 ET
United Therapeutics published news for 2022 q2
SEC form 6
2022-09-01 06:01 ET
United Therapeutics published news for 2022 q2
SEC form 6
2022-08-03 06:06 ET
United Therapeutics published news for 2022 q2
SEC form 10
2022-08-03 06:03 ET
United Therapeutics reported for 2022 q2
SEC form 10
2022-08-03 00:00 ET
United Therapeutics reported for 2022 q2
SEC form 8
2022-08-03 00:00 ET
United Therapeutics reported for 2022 q2
SEC form 6
2022-06-28 17:08 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-05-24 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-05-04 06:08 ET
United Therapeutics published news for 2022 q1
SEC form 10
2022-05-04 06:04 ET
United Therapeutics reported for 2022 q1
SEC form 10
2022-05-04 00:00 ET
United Therapeutics reported for 2022 q1
SEC form 8
2022-05-04 00:00 ET
United Therapeutics reported for 2022 q1
SEC form 6
2022-04-29 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-04-22 06:01 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-04-01 06:13 ET
United Therapeutics published news for 2022 q1
SEC form 6
2022-02-24 06:09 ET
United Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 06:05 ET
United Therapeutics published news for 2021 q4
SEC form 10
2022-02-24 00:00 ET
United Therapeutics published news for 2021 q4
SEC form 8
2022-02-24 00:00 ET
United Therapeutics published news for 2021 q4
SEC form 6
2022-01-18 06:01 ET
United Therapeutics published news for 2021 q4
SEC form 6
2021-12-27 06:02 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-11-03 06:07 ET
United Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 06:03 ET
United Therapeutics published news for 2021 q3
SEC form 10
2021-11-03 00:00 ET
United Therapeutics published news for 2021 q3
SEC form 8
2021-11-03 00:00 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-10-18 06:01 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-10-01 06:01 ET
United Therapeutics published news for 2021 q3
SEC form 6
2021-08-19 06:00 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-08-04 06:13 ET
United Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 06:04 ET
United Therapeutics published news for 2021 q2
SEC form 10
2021-08-04 00:00 ET
United Therapeutics published news for 2021 q2
SEC form 8
2021-08-04 00:00 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-07-14 06:15 ET
United Therapeutics published news for 2021 q2
SEC form 6
2021-06-25 16:30 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-23 06:01 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-16 06:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-07 06:01 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-06-03 06:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-05-05 06:17 ET
United Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 06:10 ET
United Therapeutics published news for 2021 q1
SEC form 10
2021-05-05 00:00 ET
United Therapeutics published news for 2021 q1
SEC form 8
2021-05-05 00:00 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-29 06:06 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-19 06:02 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-04-01 06:03 ET
United Therapeutics published news for 2021 q1
SEC form 6
2021-03-03 06:02 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-24 06:09 ET
United Therapeutics published news for 2020 q4
SEC form 10
2021-02-24 06:07 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-10 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-02-05 06:05 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-28 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-22 06:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2021-01-13 17:01 ET
United Therapeutics published news for 2020 q4
SEC form 6
2020-12-28 06:08 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-12-09 06:00 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-12-02 06:01 ET
United Therapeutics published news for 2020 q3
SEC form 6
2020-10-28 06:21 ET
United Therapeutics published news for 2020 q3
SEC form 10
2020-10-28 06:12 ET
United Therapeutics published news for 2020 q3